header image

Global Development Pipeline

Ongoing Work in Immunotherapy

 

Other neurodegenerative and immunological disorders, including mild cognitive impairment (MCI), dermatomyositis (DM), and chronic inflammatory demyelinating polyneuropathy (CIDP), are major clinical focus areas for our team. The role of immunoglobulin therapy for managing the symptoms of MCI, DM, and CIDP is being explored in clinical trials with octagam®.

 

Post-marketing studies are ongoing to further strengthen the body of evidence on the tolerability of octagam®. New high-yield intravenous and subcutaneous IG formulations are also under advanced stages of development.

 

Ongoing Work in Critical Care

A new fibrinogen product is currently under development, addressing yet another essential area in critical care. Fibrinogen (Factor I) is a soluble plasma glycoprotein that is converted into fibrin and helps stop bleeding by promoting blood clot formation. Fibrinogen is used to treat bleeding episodes in people with congenital fibrinogen deficiency. Although it is a rare disease, the prevalence of congenital fibrinogen deficiency should not be underestimated. It varies from silent forms with almost no symptoms over a long period of time, from moderate bleeding to severe events such as intracerebral bleeding.

 

We have also developed and commercialized universal plasma that can be used for any patient regardless of blood group. The universal profile of this product is ensured by mixing plasma of A, B, and AB types in predetermined ratios for the neutralization of anti-A and     anti-B by free A and B substance.

 

Lyophilized universal plasma is in clinical development for immediate reconstitution and infusion without the need for cold storage, thawing or blood typing. This will be a key advantage in emergency infusions when time is of the essence.

 

Ongoing Work in Hematology 

 

Our understanding of hemophilia and other bleeding disorders is leveraged in our pioneering products for the treatment of hemophilia A and von Willebrand disease (vWD).

 

Making Good Great

 

Enhancing existing therapies is also a crucial mandate of our team. Improving the ease of use, convenience and flexibility in dosing are all important aspects of patient care, and we continually invest in making these enhancements possible across our entire product range.

 

R&D Pipeline Area

Description

Therapeutic Area

HGF

Human growth factor

Wound Healing

NewNorm

New high-yield subcutaneous IG

Immunotherapy

Octanate 1000 5ml

1000 IU vials

Hematology

Lyoplas

Lyophilised S/D plasma in bags

Critical Care

Fibrinogen 

IV concentrate for inherited/ acquired deficiency 

Critical Care